UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

Ultrasensitive ctDNA Detection in Advanced Renal Cell Carcinoma - Juan Ruiz-Bañobre

Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...
UroToday

Managing Low-Volume Metachronous Metastatic Hormone-Sensitive Prostate Cancer - Pedro Barata

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
UroToday

ASCO 2026: Early Results of COMPPARE, a Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer

(UroToday.com) The 2026 American Society of Clinical Oncology Genitourinary (ASCO) Annual Meeting held in Chicago, IL, was host to the Prostate, Testicular, and Penile Cancer - Rapid Oral Abstracts ...
UroToday

AUA 2026: Impact of Anemia and Its Management on Quality of Life in Metastatic Castration-resistant Prostate Cancer Patients Treated with Talazoparib Plus Enzalutamide

(UroToday.com) The 2026 American Urological Association (AUA) Annual Meeting featured a poster presentation by Dr. Neal Shore and colleagues evaluating the impact of anemia and anemia-directed ...
UroToday

APCCC 2026: Can Genomics/Artificial Intelligence Help to Minimize Over- or Undertreatment?

(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a high-risk and locally advanced prostate cancer session and a presentation by Dr. Jason Efstathiou ...
UroToday

EAU 2026 Press Releases

Co-PSMA Data Presented at EAU Annual Congress 2026 with Manuscript Accepted for Publication in the European Urology Journal Photocure: Trials in Progress Presented at the European Association of ...
UroToday

AUA 2025: New Artificial Urinary Sphincter: Results of the First in Man Study at One-Year Post-Activation (SOPHIA Study)

(UroToday.com) Dr. Chartier-Kastler (sponsored by UroMems) presented their findings on the UroActive TM implantable electronic artificial urinary sphincter (AUS), aimed at treating male stress urinary ...
UroToday

ASCO GU 2025: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib in Combination with Androgen Receptor Pathway Inhibitors ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Arun Azad discussing EvoPAR-Prostate01, a phase III, double-blind, ...
UroToday

AUA 2024: AUA Guidelines: Salvage Therapy for Prostate Cancer

(UroToday.com) The 2024 American Urological Association (AUA) annual meeting featured a plenary session, and a presentation by Dr. Todd Morgan discussing the AUA guidelines for salvage therapy for ...
UroToday

ESMO 2023: MEDI5752 (Volrustomig), a Novel PD-1/CTLA-4 Bispecific Antibody, in the First-Line Treatment of 65 Patients with Advanced Clear Cell Renal Cell Carcinoma

(UroToday.com) The 2023 European Society of Medical Oncology (ESMO) Annual Congress held in Madrid, Spain between October 20 th and 24 th, 2023 was host to a non-prostate, genitourinary tumors mini ...
UroToday

ASTRO 2021: RTOG 0926: Phase II Protocol Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemo ...

(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a presentation by Dr. Jason Efstathiou discussing results of the NRG Oncology/RTOG 0926 trial.